Business
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo CAMBRIDGE, Mass.,
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo\nCAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2025 (ASN Kidney Week), which will take place in Houston, TX from November 5-9, 2025. ASN Kidney Week attendees can also visit Akebia at Booth #903 in the Exhibit Hall. Dr. Glenn M. Chertow of Stanford University will present the results of a win odds analysis of all-cause mortality and hospitalization from the INNO2VATE trials, part of the global Phase 3 clinical development programs for vadadustat. In the U.S., Vafseo® (vadadustat) is approved for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Additionally, four posters will present data to inform dosing of vadadustat as well as information on ongoing real-world evidence studies, including the VOICE and VOCAL trials. “We remain actively engaged with the nephrology community as we conduct multiple clinical real-world evidence studies and identify potential additional clinical benefits of Vafseo,” said Steven Burke, MD, Senior Vice President and Chief Research & Development Officer at Akebia. “Generating, evaluating and sharing data are critical to ensuring healthcare providers have the information they need to make informed decisions about treating patients with Vafseo and to further the medical and scientific communities’ understanding about this new, innovative medicine.” Oral presentation details: Win-Odds Analysis of Deaths and Hospitalization in Patients taking Vadadustat or Darbepoetin Alfa for CKD-Related Anemia Undergoing DialysisPresenter: Glenn M. Chertow, MDSession Title: Hemodialysis: Novel Interventions Session Date/Time: November 6, 2025; 4:30 PM to 6:00 PMSession Room: Room 351D (Convention Center) Akebia-supported posters to be presented at ASN Kidney Week 2025 in the Exhibit Hall: Model-Based VAFSEO Starting Dose Recommendations in Dialysis-Dependent CKD Patients Poster #: TH-PO902November 6, 2025; 10:00 AM-12:00 PM CDT Vadadustat Outcomes In-Center Experien...